Last reviewed · How we verify
DNA degradation twice daily
This drug promotes the degradation of DNA, likely through enzymatic or chemical mechanisms that break down genetic material.
At a glance
| Generic name | DNA degradation twice daily |
|---|---|
| Also known as | lytics twice daily, DNase twice daily |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
DNA degradation as a therapeutic approach may work by targeting rapidly dividing cells (such as cancer cells or pathogens) that depend on intact DNA for replication. The twice-daily dosing suggests a short half-life or need for sustained exposure. The mechanism could involve nuclease activity, topoisomerase inhibition, or other DNA-damaging pathways, though the specific molecular target is unclear from the description provided.
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
- Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema (PHASE4)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DNA degradation twice daily CI brief — competitive landscape report
- DNA degradation twice daily updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI